Genprex, Inc. (GNPX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Genprex, Inc. is a clinical-stage gene therapy company focused on oncology (REQORSA) and diabetes (GPX-002) programs. This report covers the quarterly period ended June 30, 2025. The company operates as a single segment and is currently incurring significant losses while advancing clinical trials. As of August 1, 2025, there were 33,466,784 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4,674,901) | $(8,639,503) | $(12,464,714) |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.40) | $(6.59) |
| Operating Expenses | $4,681,784 | $8,651,076 | $12,515,000 |
| Cash and Cash Equivalents (End of Period) | $1,346,844 | $1,346,844 | $2,459,024 |
| Net Cash Used in Operating Activities | N/A | $(8,025,660) | $(11,867,211) |
| Net Cash Provided by Financing Activities | N/A | $7,770,844 | $6,813,961 |
Liquidity: The company reported a working capital deficit of approximately $380,000 ($2.06M current assets vs. $2.44M current liabilities) as of June 30, 2025. Management estimates current cash will fund operations through the end of August 2025.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by 31% year-over-year for the six-month period, primarily due to the closure of the Acclaim-2 clinical trial and significant expense reduction strategies (reduced headcount from 21 to 15 employees, lower travel, and fewer professional service providers).
- General & Administrative (G&A): G&A expenses dropped 52% year-over-year (from $7.57M to $3.61M) due to the aforementioned cost-cutting measures.
- Research & Development (R&D): R&D expenses increased slightly by 2% year-over-year (from $4.94M to $5.04M). This increase is attributed to the absence of a $1.165M one-time refund from a contract manufacturer recorded in the prior year, offset by reduced clinical expenses from closing the Acclaim-2 trial.
- Capital Structure: The company significantly increased its share count, issuing over 22 million shares in the first half of 2025 through its ATM facility and a new Equity Line of Credit (ELOC), compared to approximately 1 million shares in the same period in 2024.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing. No adjustments have been made to asset recoverability or liability classification.
- Capital Raising: The company entered a $12.5M ELOC with Lincoln Park Capital in June 2025. As of the filing date, the company has utilized the full 19.99% exchange cap (5.56M shares) allowed under Nasdaq rules without shareholder approval. Further sales require shareholder approval or meeting specific average price conditions.
- Nasdaq Compliance: The company received notice from Nasdaq on August 12, 2025, regarding potential delisting due to failure to maintain the $1.00 minimum bid price requirement. The company intends to request a hearing and may consider a reverse stock split.
- Clinical Outlook:
- Acclaim-1 (NSCLC): Phase 2a expansion is enrolling ~33 patients; interim analysis expected in H1 2026.
- Acclaim-3 (SCLC): Phase 2 expansion is enrolling ~50 patients; interim analysis expected in Q1 2026.
- Acclaim-2: Enrollment ceased in August 2024.
- Diabetes: Preclinical studies ongoing; seeking FDA guidance for IND-enabling studies in H2 2025.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and insufficient accounting personnel depth.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding immediately, as management projects cash sufficiency only through August 2025.
- Shareholder Approval: Monitor the outcome of the upcoming 2025 Annual Meeting regarding the approval to exceed the ELOC exchange cap.
- Nasdaq Status: Track the status of the hearing request regarding the $1.00 bid price delisting notice and any potential reverse stock split announcements.
- Internal Controls: Review the progress of remediation efforts for the identified material weaknesses in financial reporting.
- Clinical Milestones: Confirm enrollment rates for Acclaim-1 and Acclaim-3 trials to ensure they meet the Q1 2026 interim analysis targets.